Evercore Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

Research analysts at Evercore initiated coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “outperform” rating on the biotechnology company’s stock.

VTVT has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $47.00 target price (up from $36.00) on shares of vTv Therapeutics in a research note on Friday, December 19th. TD Cowen began coverage on shares of vTv Therapeutics in a research report on Monday, January 5th. They issued a “buy” rating for the company. Wall Street Zen upgraded vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. BTIG Research reissued a “buy” rating and issued a $49.00 target price on shares of vTv Therapeutics in a research note on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, vTv Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $53.00.

vTv Therapeutics Stock Down 1.3%

NASDAQ:VTVT opened at $33.28 on Thursday. vTv Therapeutics has a 12-month low of $14.00 and a 12-month high of $44.00. The stock’s fifty day simple moving average is $35.93 and its 200-day simple moving average is $29.42. The firm has a market capitalization of $131.12 million, a P/E ratio of -9.93 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.51. The company had revenue of ($0.02) million during the quarter.

Institutional Trading of vTv Therapeutics

Institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. bought a new position in shares of vTv Therapeutics during the 4th quarter worth approximately $221,000. Geode Capital Management LLC raised its stake in vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after acquiring an additional 12,896 shares during the period. 683 Capital Management LLC acquired a new stake in vTv Therapeutics during the 4th quarter valued at $731,000. Finally, Baker BROS. Advisors LP lifted its holdings in vTv Therapeutics by 52.4% during the 3rd quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares during the last quarter. Institutional investors own 17.51% of the company’s stock.

Key vTv Therapeutics News

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.